Compare HSBC Holdings plc (HSBC) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs McKesson Corporation — how do they compare? HSBC Holdings plc trades at $92.83 (market cap $311.92B), while McKesson Corporation trades at $931.59 (market cap $108.46B). The key difference: HSBC Holdings plc is far larger — about 2.9× McKesson Corporation's market cap, and HSBC Holdings plc pays the higher dividend (4.05%). Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and McKesson Corporation for 74 Days on average.
| HSBC | MCK | |
|---|---|---|
Market Cap | $311.92B | $108.46B |
Volume | 3,546,658 | 712,607 |
Sector | Financials | Health |
52-Week High | $107.86 | $995.69 |
52-Week Low | $65.67 | $725.17 |
Typical Hold Time | 36 Days | 74 Days |
Enterprise Value | $222.19B | $115.00B |
Dividend Yield | 4.05% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.80, down 0.97% with bearish technical signals. The stock shows strong profitability with 34.54% net margin and reasonable valuation at 13.23 P/E. Recent earnings were mixed with Q2 beat but Q1 miss. Analyst sentiment is cautious with 38% buy ratings. The bank is expanding in technology banking and US wealth services while restructuring European operations.
HSBC offers value with solid fundamentals but faces near-term headwinds from technical weakness and mixed earnings performance. Growth opportunities in Asian markets and wealth management balance risks from European restructuring and CFO transition in 2027.
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
